Naringenin treatment suppressed proliferation and migration of B16F10 murine and SK-MEL-28 human melanoma cell lines by inhibiting the phosphorylation of ERK1/2 and JNK MAPKs. The gene discussed is MAPK3; the disease is melanoma.